AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26801468 — intervention group
Group type: COMPARATOR
Intervention: Survey layout with all questions on one screen and vertical scrolling
Number of subjects: 0
Study 26801468 — intervention group
Group type: COMPARATOR
Intervention: Survey layout with a single question per screen and multiple pages
Number of subjects: 0
Study 24365987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole at a dose of 0.5 mg/kg twice daily
Number of subjects: 40
Study 24365987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole at a dose of 1 mg/kg twice daily
Number of subjects: 40
Study 22453270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 6-month weight loss program
Number of subjects: 338
Study 22453270 — intervention group
Group type: COMPARATOR
Intervention: Educational program (control)
Number of subjects: 338
Study 19464207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Number of subjects: 16
Study 19464207 — intervention group
Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 16
Study 17325558 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 76)
Number of subjects: 226
Study 17325558 — intervention group
Group type: EXPERIMENTAL
Intervention: PG4 group (control formula supplemented with 4 g/L of a prebiotic blend, n = 74)
Number of subjects: 226
Study 17325558 — intervention group
Group type: EXPERIMENTAL
Intervention: PGL8 group (control formula supplemented with 8 g/L of a prebiotic blend, n = 76)
Number of subjects: 226
Study 14723561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 400 mg/m2 initial dose followed by 250 mg/m2 weekly plus irinotecan (various doses)
Number of subjects: 0
Study 14723561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with irinotecan, fluorouracil and folinic acid (various regimens)
Number of subjects: 0
Study 14723561 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab monotherapy
Number of subjects: 0
Study 14723561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus irinotecan
Number of subjects: 0
Study 11728945 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX‐2 inhibitors
Number of subjects: 0
Study 9509201 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (IG)
Number of subjects: 20
Study 9509201 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PG)
Number of subjects: 20
Study 7920748 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue, goserelin (Zoladex), 3.6 mg/inj monthly for 6 months
Number of subjects: 27
Study 7920748 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 women with normal menstrual cycles)
Number of subjects: 27
Study 3183305 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (anticholinergic)
Number of subjects: 0
Study 3183305 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine plus physostigmine (anticholinesterase)
Number of subjects: 0
Study 3183305 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine plus methylphenidate (adrenergic)
Number of subjects: 0
Study 3183305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31499227 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention with 10 live coaching sessions delivered virtually by health coaches using tablets.
Number of subjects: 250
Study 31499227 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention
Number of subjects: 250
Study 31499227 — intervention group
Group type: COMPARATOR
Intervention: Standardized health information via tablets
Number of subjects: 250
Study 28596245 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive-behavioural therapy (cCBT)
Number of subjects: 52
Study 28596245 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric treatment as usual (TAU)
Number of subjects: 52
Study 26545527 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt with added whey protein (PSL)
Number of subjects: 20
Study 26545527 — intervention group
Group type: COMPARATOR
Intervention: Chocolate
Number of subjects: 20
Study 26545527 — intervention group
Group type: COMPARATOR
Intervention: Biscuits
Number of subjects: 20
Study 23319454 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cognitive Behavioral Therapy (mCBT)
Number of subjects: 59
Study 23319454 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 59
Study 21764662 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose tirofiban (HDT)
Number of subjects: 1370
Study 21764662 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no HDT)
Number of subjects: 1370
Study 19591158 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 8
Study 19591158 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 8
Study 16999648 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 502
Study 16999648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 502
Study 12393605 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD/HAM double induction, TAD consolidation, and either maintenance therapy or S-HAM consolidation
Number of subjects: 449
Study 12393605 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 16 blasts (continuous variable)
Number of subjects: 449
Study 12393605 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 449
Study 12393605 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival (EFS)
Number of subjects: 449
Study 12393605 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse-free survival (RFS)
Number of subjects: 449
Study 12393605 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analyses for CR rate
Number of subjects: 449
Study 12393605 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analyses for OS
Number of subjects: 449
Study 12393605 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analyses for EFS
Number of subjects: 449
Study 12393605 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analyses for RFS
Number of subjects: 449
Study 11004254 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoastigmatic refractive keratectomy with the Summit Apex Plus excimer laser
Number of subjects: 56
Study 8648777 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral fleroxacin once daily
Number of subjects: 75
Study 8648777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 1397701 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (60% of total energy from carbohydrates)
Number of subjects: 8
Study 1397701 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet (35% of total energy from carbohydrates)
Number of subjects: 8
Study 1397701 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemic glucose clamp study
Number of subjects: 8
Study 6145727 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 577
Study 6145727 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 577
Study 6145727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 577
Study 6145727 — intervention group
Group type: COMPARATOR
Intervention: No drug therapy (control)
Number of subjects: 577
Study 6145727 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenothiazine-treated groups (chlorpromazine and fluphenazine)
Number of subjects: 577
Study 6145727 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenothiazine-treated patients
Number of subjects: 577
Study 31895286 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Active Recovery (LAR - 8 minutes)
Number of subjects: 0
Study 31895286 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Passive Recovery (LPR - 8 minutes)
Number of subjects: 0
Study 31895286 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Passive Recovery (SPR - 2 minutes)
Number of subjects: 0
Study 31895286 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Active Recovery (SAR - 2 minutes)
Number of subjects: 0
Study 31520897 — intervention group
Group type: EXPERIMENTAL
Intervention: apabetalone 100 mg orally twice daily
Number of subjects: 2425
Study 31520897 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2425
Study 30696670 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler education programme with teach-to-goal placebo-device training
Number of subjects: 146
Study 30696670 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study 28964963 — intervention group
Group type: EXPERIMENTAL
Intervention: Local endometrial injury (scratch) performed in 40 patients
Number of subjects: 80
Study 28964963 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 patients without local endometrial injury)
Number of subjects: 80
Study 25855534 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli that allowed early visual processing stages (Experiments 1-3)
Number of subjects: 0
Study 25855534 — intervention group
Group type: COMPARATOR
Intervention: Visual stimuli that obstructed early visual processing stages (Experiments 1-3)
Number of subjects: 0
Study 25855534 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible Necker cubes (Experiments 4 and 5)
Number of subjects: 0
Study 25855534 — intervention group
Group type: COMPARATOR
Intervention: Impossible Necker cubes (Experiments 4 and 5)
Number of subjects: 0
Study 25855534 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial muscle responses (zygomaticus activity; Experiments 3 and 7)
Number of subjects: 0
Study 25855534 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal preference ratings (Experiments 1, 2, and 4)
Number of subjects: 0
Study 23924261 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (240 mg/day)
Number of subjects: 32
Study 23924261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21854144 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitments to change (CTC) made immediately after the lecture
Number of subjects: 144
Study 21854144 — intervention group
Group type: COMPARATOR
Intervention: Commitments to change (CTC) made 7 days post-lecture
Number of subjects: 144
Study 21854144 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitments made by participants from either group
Number of subjects: 144
Study 20008230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 0
Study 20008230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 0
Study 20008230 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study 20008230 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 20008230 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel monoclonal antibodies targeting CD20, CD23, or CD40
Number of subjects: 0
Study 20008230 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavopiridol, Oblimersen, Lenalidomide
Number of subjects: 0
Study 20008230 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity allogeneic progenitor cell transplantation
Number of subjects: 0
Study 20008230 — intervention group
Group type: EXPERIMENTAL
Intervention: New prognostic markers
Number of subjects: 0
Study 17240066 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 2
Study 17240066 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 2
Study 15520364 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 to 40 mg/d)
Number of subjects: 246
Study 15520364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 to 45 mg/d)
Number of subjects: 246
Study 11883741 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg administered once daily via Turbuhaler
Number of subjects: 0
Study 11883741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9683002 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 (3 g MgSO4 between 2030 hours and 2100 hours, followed by 0.5 g MgSO4 per hour until 0700 hours)
Number of subjects: 10
Study 9683002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9683002 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4
Number of subjects: 10
Study 8062317 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem XR (240 mg, then 480 mg after 4 weeks if DBP > 90 mm Hg)
Number of subjects: 350
Study 8062317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 8062317 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem XR
Number of subjects: 350
Study 8062317 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem XR and Placebo
Number of subjects: 350
Study 3045726 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 105
Study 3045726 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 105
Study 3045726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tamoxifen and aminoglutethimide
Number of subjects: 105
Study 29678370 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg octanoic acid (OA)
Number of subjects: 18
Study 29678370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26179823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial self‐adhesive prescriptions
Number of subjects: 54
Study 26179823 — intervention group
Group type: COMPARATOR
Intervention: Handwritten drug charts
Number of subjects: 54
Study 26179823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial printed labels
Number of subjects: 54
Study 26188642 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFAs (1.4 g of eicosapentaenoic and docosahexaeonic acids)
Number of subjects: 23
Study 26188642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 23
Study 26188642 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFAs
Number of subjects: 23
Study 26188642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24307845 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated alendronate (5 mg) and calcitriol (0.5 µg) combined drug (Maxmarvil)
Number of subjects: 33
Study 24307845 — intervention group
Group type: COMPARATOR
Intervention: Alendronate only
Number of subjects: 33
Study 22194858 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB with omentectomy
Number of subjects: 21
Study 22194858 — intervention group
Group type: COMPARATOR
Intervention: RYGB non-omentectomy
Number of subjects: 21
Study 22194858 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB with and without omentectomy
Number of subjects: 21
Study 19446459 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 44
Study 19446459 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Sound
Number of subjects: 44
Study 19446459 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic Environment Importance
Number of subjects: 44
Study 16563996 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose brachytherapy (12 Gy)
Number of subjects: 95
Study 15262613 — intervention group
Group type: EXPERIMENTAL
Intervention: Transxiphoid approach for ASD/VSD repair
Number of subjects: 26
Study 15262613 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic model used in a prospective study
Number of subjects: 26
Study 10718834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stimulation with CRH (100 micrograms i.v.) plus desmopressin (10 micrograms i.v.) during BIPSS
Number of subjects: 34
Study 10718834 — intervention group
Group type: COMPARATOR
Intervention: CRH stimulation alone (100 micrograms i.v.) during BIPSS
Number of subjects: 34
Study 10718834 — intervention group
Group type: COMPARATOR
Intervention: CRH stimulation in oEAS patients
Number of subjects: 34
Study 10718834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stimulation in oEAS patient
Number of subjects: 34
Study 9327193 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (2.5 mg once-daily)
Number of subjects: 61
Study 9327193 — intervention group
Group type: COMPARATOR
Intervention: Captopril (6.25 mg twice-daily)
Number of subjects: 61
Study 9327193 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril and Captopril (both groups)
Number of subjects: 61
Study 8096941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 282777
Study 6942649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable leaves and stalks
Number of subjects: 0
Study 6942649 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grains
Number of subjects: 0
Study 6942649 — intervention group
Group type: COMPARATOR
Intervention: Sucrose supplement
Number of subjects: 0
Study 30383312 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive brain stimulation (NIBS) over the primary sensorimotor missing hand cortex (S1/M1) during phantom hand movements.
Number of subjects: 0
Study 30383312 — intervention group
Group type: COMPARATOR
Intervention: NIBS intervention
Number of subjects: 0
Study 28390444 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention for OCD
Number of subjects: 46
Study 28390444 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscientiousness scores
Number of subjects: 46
Study 26449137 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite
Number of subjects: 28
Study 26449137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 24044799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 94
Study 24044799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 21077956 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous self-improvement intervention (n = 8)
Number of subjects: 15
Study 21077956 — intervention group
Group type: COMPARATOR
Intervention: Attention control management (n = 5)
Number of subjects: 15
Study 19367517 — intervention group
Group type: EXPERIMENTAL
Intervention: Amputee Mobility Aid
Number of subjects: 0
Study 19367517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic Post‐Amputation Aid
Number of subjects: 0
Study 17971939 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial stage group (44 cases)
Number of subjects: 148
Study 17971939 — intervention group
Group type: COMPARATOR
Intervention: After initial stage group (104 cases)
Number of subjects: 148
Study 17971939 — intervention group
Group type: EXPERIMENTAL
Intervention: Common type group (87 cases)
Number of subjects: 148
Study 17971939 — intervention group
Group type: COMPARATOR
Intervention: Severe type group (61 cases)
Number of subjects: 148
Study 17971939 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilobar lung involvement group (49 cases)
Number of subjects: 148
Study 17971939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilobar lung involvement group (53 cases)
Number of subjects: 148
Study 17971939 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse lung involvement group (46 cases)
Number of subjects: 148
Study 16789405 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured cardiac rehabilitation program (CRP)
Number of subjects: 104
Study 16789405 — intervention group
Group type: COMPARATOR
Intervention: General cardiology clinic (GC)
Number of subjects: 104
Study 16789405 — intervention group
Group type: COMPARATOR
Intervention: Planned coronary follow-up program (FUP)
Number of subjects: 104
Study 14512699 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% inspired isoflurane concentration (C(I)iso)
Number of subjects: 16
Study 14512699 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% inspired isoflurane concentration (C(I)iso)
Number of subjects: 16
Study 10352053 — intervention group
Group type: EXPERIMENTAL
Intervention: New intravenous therapy protocol
Number of subjects: 219
Study 10352053 — intervention group
Group type: COMPARATOR
Intervention: Old intravenous therapy protocol
Number of subjects: 219
Study 10352053 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' judgments related to intravenous therapy initiation
Number of subjects: 219
Study 8618811 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuEPO treatment for 12 months
Number of subjects: 27
Study 8618811 — intervention group
Group type: COMPARATOR
Intervention: non-EPO group (clinical monitoring)
Number of subjects: 27
Study 8618811 — intervention group
Group type: COMPARATOR
Intervention: HD group (hemodialyzed patients with haematocrit > 30%)
Number of subjects: 27
Study 8618811 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 27
Study 2202791 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (AC) for 2 months
Number of subjects: 2194
Study 2202791 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF) for 6 months
Number of subjects: 2194
Study 2202791 — intervention group
Group type: EXPERIMENTAL
Intervention: AC followed by IV CMF
Number of subjects: 2194
Study 2202791 — intervention group
Group type: EXPERIMENTAL
Intervention: AC therapy
Number of subjects: 2194
Study 6814757 — intervention group
Group type: EXPERIMENTAL
Intervention: V-PLAT (VM-26, cisplatin, and prednisone)
Number of subjects: 123
Study 6814757 — intervention group
Group type: COMPARATOR
Intervention: V-HEX (VM-26, hexamethylmelamine, and prednisone)
Number of subjects: 123
Study 6814757 — intervention group
Group type: EXPERIMENTAL
Intervention: V-PLAT
Number of subjects: 123
Study 6814757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both V-PLAT and V-HEX
Number of subjects: 123
Study 6814757 — intervention group
Group type: EXPERIMENTAL
Intervention: VM-26 and hexamethylmelamine as single agents
Number of subjects: 123
Study 30590411 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid (400 or 800 μg per day)
Number of subjects: 622
Study 30590411 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (3 g per day)
Number of subjects: 622
Study 30590411 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid (800 µg)
Number of subjects: 622
Study 30590411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study 28655901 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic sleep restriction (3 weeks, 5 nights of 4 hours sleep followed by 2 nights of 8 hours sleep)
Number of subjects: 0